Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar basliginda one cikan gelisme: The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.